Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Report 2022 to 2030

Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis

$ 3999

Egypt's Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is expected to grow from $10 Mn in 2022 to $25 Mn in 2030 with a CAGR of 11.70% for the year 2022-30. The introduction of new treatment alternatives in the Egypt market may result from pharmaceutical companies' investments in the research and development of novel PNH therapies. The market is segmented by therapy, diagnostic test, and distribution channels. Some key players in this market include Amoun Pharmaceutical, EIPICO, Minapharm Pharmaceuticals, Pharco Pharmaceuticals, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Akari Therapeutics, Amgen, CSL Behring, and Bioverativ.

CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Jigyasu Bhandari

Buy Now

Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Executive Analysis

Egypt's Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is expected to grow from $10 Mn in 2022 to $25 Mn in 2030 with a CAGR of 11.70% for the year 2022-30. Only 5.2% of the overall budget, or 1.5% of GDP, was allotted to the health sector by the Egyptian government through 2021. The budget's share of health expenses declined, reaching its lowest level in the preceding five years, from 5.3% in 2016 to 4.9% in 2019. 1.6% of GDP is a record high for government spending on health. In Egypt, public health expenditures have risen to around 3% of GDP.

In Egypt, red blood cell synthesis is impacted by the rare and deadly blood condition known as Paroxysmal Nocturnal Hemoglobinuria (PNH). A genetic change in the bone marrow stem cells that result in PNH causes the formation of defective red blood cells that are vulnerable to being destroyed by the immune system. People in Egypt who think they may have PNH or are exhibiting signs of the condition should see a doctor right away so they can be properly diagnosed and treated. They should also work with their healthcare provider to choose the best course of action. Fatigue, shortness of breath, stomach pain, and blood in the urine are a few of the PNH's typical symptoms. PNH can be treated with blood transfusions, symptom-controlling medicines, and bone marrow transplants.

egypt paroxysmal nocturnal hemoglobinuria therapeutics market

Market Dynamics

Market Growth Drivers

In recent years, the Egyptian government has made investments to improve and extend the nation's healthcare system. This entails building more hospitals and clinics and spending money on modern tools and technology. As a result, more patients might gain access to PNH medicines and diagnostic tests. The introduction of new treatment alternatives in the Egyptian market may result from pharmaceutical companies' investments in the research and development of novel PNH therapies. The Egyptian government has been working to improve the regulatory climate for pharmaceutical businesses. This includes expediting the procedure for drug approval and offering fresh incentives for businesses to fund R&D in the nation.

Market Restraints

Some PNH treatments might not be offered in Egypt or might only be offered at exorbitant costs. This can restrict patients' access to efficient medicines and have an adverse effect on market expansion. Egypt has faced economic difficulties recently, including high rates of unemployment and inflation. These financial difficulties may make it more difficult for people to afford PNH therapies and reduce government spending on healthcare. Even though PNH is becoming more widely known in Egypt, many patients might not yet be aware of the disorder or its signs and symptoms. Delays in diagnosis and treatment may result from this, which would shrink the market for PNH medicines.

Competitive Landscape

Key Players

Amoun Pharmaceutical (EG)
EIPICO (EG)
Minapharm Pharmaceuticals (EG)
Pharco Pharmaceuticals (EG)
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
Akari Therapeutics
Amgen
CSL Behring
Bioverativ

Healthcare Policies and Regulatory Landscape

The Ministry of Health and Population (MoHP) and the Egyptian Drug Authority (EDA) are in charge of Egypt's healthcare laws and regulations. The EDA is in charge of overseeing and approving pharmaceutical items in the nation. The pharmaceutical sector is heavily controlled in Egypt, and before any pharmaceutical items can be advertised and sold there, they must first be approved by the EDA. To guarantee that all medications fulfil the necessary safety, effectiveness, and quality requirements, the EDA employs a strict procedure. In order to verify that good manufacturing practises (GMP) and other standards are being followed, the EDA also performs routine inspections of manufacturing sites. The Egyptian government has put in place a number of measures to increase individuals' access to healthcare, including free basic healthcare at public clinics and hospitals. Additionally, the government launched the Universal Health Insurance (UHI) programme to offer low-income and vulnerable communities financial security.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Segmentation

By Therapy

Medication Therapy
Stem Cell Therapy
Blood Transfusion Therapy

By Diagnostic Tests

CBC
LHD
Bone Marrow Examination
Flow Cytometry

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.